125 related articles for article (PubMed ID: 33610559)
1. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
2. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
Maresca L; Stecca B; Carrassa L
Cells; 2022 Apr; 11(9):. PubMed ID: 35563772
[TBL] [Abstract][Full Text] [Related]
4.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
5. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
6. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract][Full Text] [Related]
7. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
Principe DR; Narbutis M; Koch R; Rana A
Sci Rep; 2020 Nov; 10(1):20223. PubMed ID: 33214570
[TBL] [Abstract][Full Text] [Related]
8. PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
Fröhlich LM; Villar-Miyar A; Heintze T; Sauer B; Schittek B
Int J Cancer; 2024 Jul; 155(2):203-210. PubMed ID: 38619111
[TBL] [Abstract][Full Text] [Related]
9. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
Póti Á; Gyergyák H; Németh E; Rusz O; Tóth S; Kovácsházi C; Chen D; Szikriszt B; Spisák S; Takeda S; Szakács G; Szallasi Z; Richardson AL; Szüts D
Genome Biol; 2019 Nov; 20(1):240. PubMed ID: 31727117
[TBL] [Abstract][Full Text] [Related]
10. Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
Chabot C; Italiano A; Crombé A; Soubeyran I; Laizet Y; Khalifa E; Cousin S
Oncologist; 2024 May; 29(5):452-455. PubMed ID: 38558248
[TBL] [Abstract][Full Text] [Related]
11. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract][Full Text] [Related]
12. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application.
Xie H; Wang W; Qi W; Jin W; Xia B
Front Immunol; 2021; 12():661115. PubMed ID: 34712221
[TBL] [Abstract][Full Text] [Related]
14. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma.
Cleary JM; Wolpin BM; Dougan SK; Raghavan S; Singh H; Huffman B; Sethi NS; Nowak JA; Shapiro GI; Aguirre AJ; D'Andrea AD
Clin Cancer Res; 2021 Dec; 27(24):6622-6637. PubMed ID: 34285063
[TBL] [Abstract][Full Text] [Related]
15. Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy.
Dennis MJ; Bylsma S; Madlensky L; Pagadala MS; Carter H; Patel SP
Front Immunol; 2024; 15():1322187. PubMed ID: 38348036
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular findings in primary malignant melanoma of the esophagus: A multicenter study.
Deng L; Wang HY; Hu CF; Liu XY; Jiang K; Yong JJ; Wu XY; Guo KH; Wang F
Pigment Cell Melanoma Res; 2024 May; 37(3):363-371. PubMed ID: 38158377
[TBL] [Abstract][Full Text] [Related]
17. RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.
Jiang Y; Hu X; Wang Z; Zhang Q; Chen D; Zhao P
Invest New Drugs; 2024 Feb; 42(1):60-69. PubMed ID: 38071684
[TBL] [Abstract][Full Text] [Related]
18. Alterations in homologous recombination repair genes in prostate cancer brain metastases.
Rodriguez-Calero A; Gallon J; Akhoundova D; Maletti S; Ferguson A; Cyrta J; Amstutz U; Garofoli A; Paradiso V; Tomlins SA; Hewer E; Genitsch V; Fleischmann A; Vassella E; Rushing EJ; Grobholz R; Fischer I; Jochum W; Cathomas G; Osunkoya AO; Bubendorf L; Moch H; Thalmann G; Ng CKY; Gillessen S; Piscuoglio S; Rubin MA
Nat Commun; 2022 May; 13(1):2400. PubMed ID: 35504881
[TBL] [Abstract][Full Text] [Related]
19. Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Pilger D; Seymour LW; Jackson SP
Genes Dev; 2021 May; 35(9-10):602-618. PubMed ID: 33888558
[TBL] [Abstract][Full Text] [Related]
20. Directing the use of DDR kinase inhibitors in cancer treatment.
Brandsma I; Fleuren EDG; Williamson CT; Lord CJ
Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
